Cytokinetics (CYTK) Current Assets (2010 - 2026)
Cytokinetics (CYTK) posted quarterly Current Assets of $839.5 million for Q1 2026, down 12.19% year-over-year from $956.1 million in Q1 2025, and down 8.45% quarter-over-quarter from $917.0 million in Q4 2025.
Cytokinetics (CYTK) Current Assets (2010 - 2026) Analysis & Trends
Cytokinetics (CYTK) has reported Current Assets for 17 consecutive years, with $839.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Assets fell 12.19% year-over-year to $839.5 million; the TTM figure through Mar 2026 stood at $839.5 million (down 12.19% YoY), while the FY2025 annual figure was $917.0 million, down 17.24% from the prior year.
- Current Assets eased to $839.5 million in Q1 2026 per CYTK's latest filing, from $917.0 million in the prior quarter.
- Across five years, Current Assets topped out at $1.1 billion in Q4 2024 and bottomed at $561.4 million in Q3 2023.
- Historically, Current Assets has averaged $810.1 million across 5 years, with a median of $839.5 million in 2026.
- Annual changes were most pronounced in 2023 — Current Assets plunged 36.51% — and 2024, when it surged 82.04%.
- Cytokinetics' Current Assets stood at $795.2 million in 2022, then slipped by 21.02% to $628.1 million in 2023, then surged by 76.41% to $1.1 billion in 2024, then dropped by 17.24% to $917.0 million in 2025, then fell by 8.45% to $839.5 million in 2026.
- Business Quant data shows CYTK's Current Assets at $839.5 million in Q1 2026, $917.0 million in Q4 2025, and $977.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 8.07 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 4.03 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 7.22 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 11.83 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 1.76 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.62 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.63 Bn |
| 10 | Cytokinetics | 10.31 Bn | 9.14 Bn | 25.89 Mn | 1.21 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.21 Bn |
| Mar 31, 2026 | 839.47 Mn |
| Dec 31, 2025 | 916.98 Mn |
| Sep 30, 2025 | 977.35 Mn |
| Jun 30, 2025 | 886.54 Mn |
| Mar 31, 2025 | 956.05 Mn |
| Dec 31, 2024 | 1.11 Bn |
| Sep 30, 2024 | 1.02 Bn |
| Jun 30, 2024 | 1.07 Bn |
| Mar 31, 2024 | 638.70 Mn |
| Dec 31, 2023 | 628.05 Mn |
| Sep 30, 2023 | 561.42 Mn |
| Jun 30, 2023 | 586.58 Mn |
| Mar 31, 2023 | 680.63 Mn |
| Dec 31, 2022 | 795.19 Mn |
| Sep 30, 2022 | 884.28 Mn |
| Jun 30, 2022 | 602.25 Mn |
| Mar 31, 2022 | 623.53 Mn |
| Dec 31, 2021 | 535.67 Mn |
| Sep 30, 2021 | 494.94 Mn |